Retinoids act on receptors inside the cell nucleus that control which genes are switched on. There are two families: retinoic acid receptors (RARs) and retinoid X receptors (RXRs). Most retinoids activate only the first family. Alitretinoin activates both, which is unusual and is the reason it behaves differently from other retinoids.
In Kaposi sarcoma. Kaposi sarcoma is a cancer of the cells that line blood and lymph vessels, driven by a herpesvirus in people with weakened immune systems. Applied to a lesion, alitretinoin slows the growth of the tumor cells and pushes them toward normal maturation, and the lesion flattens and fades. It works on the skin lesions it is applied to. It does nothing for disease elsewhere in the body, which is why it is not used when systemic treatment is needed.
In chronic hand eczema. Taken by mouth, alitretinoin damps down inflammation and changes how the thickened, cracked skin of the palms behaves. It is used for the stubborn hyperkeratotic type — thick, fissured, painful hands — that has not responded to potent topical steroids. It is not a first-line eczema drug anywhere; it is what comes after strong topicals have failed.
The topical gel does not require routine blood tests. Treated lesions are reviewed periodically to see whether they are responding, and the frequency of application is adjusted up or down based on irritation.
Oral alitretinoin, in countries where it is licensed, does require monitoring: liver function, cholesterol and triglycerides, and thyroid function before starting and periodically during the course. Anyone who can become pregnant needs a negative pregnancy test before starting, monthly tests during treatment, and reliable contraception for the course and for a period afterward.
Panretin gel is slow. Most people who respond see the lesion begin to flatten and lose color over several weeks, and the label's own trials ran for 12 weeks and beyond. Some lesions respond and others on the same person do not. It is worth continuing for at least two to three months before calling it a failure, provided the skin tolerates it.
Oral alitretinoin for hand eczema typically shows meaningful change by 8 weeks, with the full effect at the end of a 12 to 24 week course. Hands that are going to clear usually clear within that window.
With the gel, Kaposi sarcoma lesions can regrow after treatment stops, since the drug controls local growth rather than eliminating the underlying disease. The most important factor in AIDS-related Kaposi sarcoma is control of HIV itself — effective antiretroviral therapy does more for the disease than any topical does.
With the oral drug, chronic hand eczema relapses in a substantial share of people after a course ends, often within months. Repeat courses are given in the countries where it is licensed, and many people who relapse respond again.
There is no withdrawal effect and no taper with either form.